Log in

NASDAQ:AMAGAMAG Pharmaceuticals Stock Price, Forecast & News

$7.93
+0.46 (+6.16 %)
(As of 05/25/2020 03:49 PM ET)
Add
Compare
Today's Range
$7.42
Now: $7.93
$8.11
50-Day Range
$6.08
MA: $7.55
$9.23
52-Week Range
$4.41
Now: $7.93
$13.53
Volume533,307 shs
Average Volume596,137 shs
Market Capitalization$271.76 million
P/E RatioN/A
Dividend YieldN/A
Beta0.98
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company's products candidates include Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women; AMAG-423, a polyclonal antibody in development for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent for the treatment of oral anticoagulants or low molecular weight heparin. It sells Feraheme to authorized wholesalers and specialty distributors. The company has a license agreement with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio LLC, Perosphere Pharmaceuticals Inc., Antares Pharma, Inc., and Abeona Therapeutics, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Read More
AMAG Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.89 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AMAG
CUSIP00163U10
Phone617-498-3300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$327.75 million
Book Value$8.44 per share

Profitability

Net Income$-466,460,000.00
Net Margins-115.05%

Miscellaneous

Employees467
Market Cap$271.76 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive AMAG News and Ratings via Email

Sign-up to receive the latest news and ratings for AMAG and its competitors with MarketBeat's FREE daily newsletter.

AMAG Pharmaceuticals (NASDAQ:AMAG) Frequently Asked Questions

How has AMAG Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

AMAG Pharmaceuticals' stock was trading at $6.62 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AMAG shares have increased by 19.8% and is now trading at $7.93. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AMAG Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AMAG Pharmaceuticals in the last year. There are currently 2 sell ratings, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for AMAG Pharmaceuticals.

When is AMAG Pharmaceuticals' next earnings date?

AMAG Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for AMAG Pharmaceuticals.

How were AMAG Pharmaceuticals' earnings last quarter?

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) issued its earnings results on Monday, May, 11th. The specialty pharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.27. The specialty pharmaceutical company had revenue of $68.66 million for the quarter, compared to analyst estimates of $64.95 million. AMAG Pharmaceuticals had a negative return on equity of 28.28% and a negative net margin of 115.05%. View AMAG Pharmaceuticals' earnings history.

What guidance has AMAG Pharmaceuticals issued on next quarter's earnings?

AMAG Pharmaceuticals updated its FY 2020 Pre-Market earnings guidance on Wednesday, March, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $230-280 million, compared to the consensus revenue estimate of $254.44 million.

What price target have analysts set for AMAG?

8 analysts have issued 12-month price objectives for AMAG Pharmaceuticals' stock. Their forecasts range from $6.00 to $13.00. On average, they expect AMAG Pharmaceuticals' share price to reach $8.88 in the next twelve months. This suggests a possible upside of 11.9% from the stock's current price. View analysts' price targets for AMAG Pharmaceuticals.

What are Wall Street analysts saying about AMAG Pharmaceuticals stock?

Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "AMAG's drug Feraheme continues to perform well. The company’s pipeline consists of promising development-stage assets. In January 2020, the company acknowledged the Makena challenges during its strategic review, resulting in the decision to divest Intrarosa and Vyleesi two sexual health treatments for women. decision will position the company well to focus on e continuing the development of its pipeline candidates ciraparantag and AMAG-423, see continued growth of Feraheme, and carry on with its work to retain patient access to Makena. Shares of the company have underperformed the industry year to date. Estimates have gone down ahead of Q1 earnings release. AMAG has a negative record of earnings surprises in the recent quarters." (5/6/2020)
  • 2. HC Wainwright analysts commented, "Our $16 price target for AMAG is based on our sum-of-the-parts NPV valuation based on each of the company’s assets; we value the company’s commercail assets, and pipeline assets, ciraparantag ($9.07) and AMG-423 ($1.75) and deduct unallocated R&D and corporate expenses ($10.78). We have negligible value for Intrarosa and MuGard. Our valuation model utilizes a discount rate of 10.4% based on the company’s WACC (Beta of 1.1, equity risk premium of 6.7%). We adjust each pipeline indication for probability of success with ciraparantag at 50% (adjusting for risk of ultimate approval as well as probability of establishing differentiated profile); and AMAG-423 at 33%." (8/8/2019)

Has AMAG Pharmaceuticals been receiving favorable news coverage?

News headlines about AMAG stock have trended somewhat positive recently, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. AMAG Pharmaceuticals earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutAMAG Pharmaceuticals.

Who are some of AMAG Pharmaceuticals' key competitors?

What other stocks do shareholders of AMAG Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AMAG Pharmaceuticals investors own include Celgene (CELG), Gilead Sciences (GILD), Palatin Technologies (PTN), Bausch Health Companies (BHC), Broadcom (AVGO), Energy Transfer LP Unit (ET), Netflix (NFLX), NVIDIA (NVDA), Ford Motor (F) and Skyworks Solutions (SWKS).

Who are AMAG Pharmaceuticals' key executives?

AMAG Pharmaceuticals' management team includes the following people:
  • Dr. William K. Heiden, CEO, Pres & Director (Age 59)
  • Mr. Edward H. Myles, Exec. VP, CFO & Treasurer (Age 47)
  • Mr. Joseph D. Vittiglio, Exec. VP of Legal Affairs and Quality, Gen. Counsel & Corp. Sec. (Age 47)
  • Dr. Julie Krop, Exec. VP of Devel. & Chief Medical Officer (Age 53)
  • Ms. Linda S. Lennox, VP of Investor Relations & Corp. Communications

What is AMAG Pharmaceuticals' stock symbol?

AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."

Who are AMAG Pharmaceuticals' major shareholders?

AMAG Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (8.44%), Geode Capital Management LLC (1.46%), Permanens Capital L.P. (1.41%), Connor Clark & Lunn Investment Management Ltd. (1.19%), Invesco Ltd. (1.04%) and Nuveen Asset Management LLC (0.96%). Company insiders that own AMAG Pharmaceuticals stock include Armistice Capital Master Fund, Armistice Capital, Llc, Camber Capital Management Lp, Elizabeth Scott Bolgiano, Joseph Vittiglio, Julie Krop and William K Heiden. View institutional ownership trends for AMAG Pharmaceuticals.

Which institutional investors are selling AMAG Pharmaceuticals stock?

AMAG stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Bleichroeder LP, Connor Clark & Lunn Investment Management Ltd., WINTON GROUP Ltd, Acadian Asset Management LLC, KBC Group NV, Two Sigma Investments LP, and Parametric Portfolio Associates LLC. View insider buying and selling activity for AMAG Pharmaceuticals.

Which institutional investors are buying AMAG Pharmaceuticals stock?

AMAG stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, AXA, AQR Capital Management LLC, Invesco Ltd., Wells Fargo & Company MN, Russell Investments Group Ltd., Permanens Capital L.P., and Strs Ohio. Company insiders that have bought AMAG Pharmaceuticals stock in the last two years include Armistice Capital Master Fund, Armistice Capital, Llc, Camber Capital Management Lp, Elizabeth Scott Bolgiano, Julie Krop, and William K Heiden. View insider buying and selling activity for AMAG Pharmaceuticals.

How do I buy shares of AMAG Pharmaceuticals?

Shares of AMAG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AMAG Pharmaceuticals' stock price today?

One share of AMAG stock can currently be purchased for approximately $7.93.

How big of a company is AMAG Pharmaceuticals?

AMAG Pharmaceuticals has a market capitalization of $271.76 million and generates $327.75 million in revenue each year. The specialty pharmaceutical company earns $-466,460,000.00 in net income (profit) each year or ($6.88) on an earnings per share basis. AMAG Pharmaceuticals employs 467 workers across the globe.

What is AMAG Pharmaceuticals' official website?

The official website for AMAG Pharmaceuticals is www.amagpharma.com.

How can I contact AMAG Pharmaceuticals?

AMAG Pharmaceuticals' mailing address is 1100 WINTER STREET, WALTHAM MA, 02451. The specialty pharmaceutical company can be reached via phone at 617-498-3300 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.